Thursday, January 15, 2015 5:26:18 PM
ARIA:
Here is the slide from the JPM presentation on reaching > 400M product revenue.
I know it may not be popular but I like the idea of trying to license Brigatinib for a descent upfront + royalty. Considering the cost to fully develop it and them not having an overvalued currency (IMO) I think its best to try to keep costs down.
Here is the slide from the JPM presentation on reaching > 400M product revenue.
I know it may not be popular but I like the idea of trying to license Brigatinib for a descent upfront + royalty. Considering the cost to fully develop it and them not having an overvalued currency (IMO) I think its best to try to keep costs down.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
